| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemagglutinin Glycoproteins, Influenza Virus | 4 | 2025 | 41 | 1.440 |
Why?
|
| HIV-1 | 16 | 2018 | 719 | 1.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2022 | 89 | 1.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2025 | 54 | 0.910 |
Why?
|
| Virion | 1 | 2025 | 121 | 0.890 |
Why?
|
| HIV Infections | 13 | 2018 | 964 | 0.850 |
Why?
|
| Influenza, Human | 3 | 2022 | 207 | 0.710 |
Why?
|
| Herpesvirus 4, Human | 6 | 2018 | 196 | 0.570 |
Why?
|
| Cytidine Deaminase | 6 | 2018 | 86 | 0.560 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 4 | 2018 | 56 | 0.460 |
Why?
|
| Electron Microscope Tomography | 2 | 2025 | 15 | 0.430 |
Why?
|
| Infectious Mononucleosis | 4 | 2016 | 34 | 0.390 |
Why?
|
| DNA, Single-Stranded | 3 | 2018 | 106 | 0.370 |
Why?
|
| Cryoelectron Microscopy | 2 | 2025 | 201 | 0.370 |
Why?
|
| Virus Replication | 5 | 2016 | 319 | 0.360 |
Why?
|
| Protein Binding | 10 | 2025 | 1606 | 0.350 |
Why?
|
| Antibodies, Viral | 4 | 2021 | 322 | 0.350 |
Why?
|
| Antibodies, Neutralizing | 4 | 2021 | 208 | 0.340 |
Why?
|
| DNA, Viral | 4 | 2016 | 232 | 0.340 |
Why?
|
| Proteins | 4 | 2018 | 751 | 0.330 |
Why?
|
| Drug Resistance, Viral | 3 | 2022 | 157 | 0.320 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 19 | 0.320 |
Why?
|
| Anti-Retroviral Agents | 3 | 2016 | 76 | 0.310 |
Why?
|
| Viral Matrix Proteins | 3 | 2016 | 50 | 0.300 |
Why?
|
| Viral Proteins | 4 | 2022 | 261 | 0.300 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 545 | 0.290 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2015 | 674 | 0.280 |
Why?
|
| Viral Tropism | 2 | 2018 | 51 | 0.280 |
Why?
|
| Genetic Variation | 4 | 2018 | 385 | 0.270 |
Why?
|
| Antiviral Agents | 4 | 2023 | 321 | 0.260 |
Why?
|
| Humans | 37 | 2025 | 62870 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 103 | 0.230 |
Why?
|
| Serine Endopeptidases | 2 | 2022 | 83 | 0.220 |
Why?
|
| Mutation | 7 | 2022 | 2599 | 0.220 |
Why?
|
| Catalytic Domain | 2 | 2017 | 198 | 0.210 |
Why?
|
| Influenza A virus | 2 | 2022 | 123 | 0.200 |
Why?
|
| Neuraminidase | 2 | 2022 | 43 | 0.200 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2002 | 11 | 0.200 |
Why?
|
| Gene Products, vpr | 1 | 2002 | 7 | 0.200 |
Why?
|
| Monocytes | 2 | 2016 | 353 | 0.190 |
Why?
|
| Oseltamivir | 1 | 2022 | 35 | 0.190 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 5 | 0.180 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2021 | 37 | 0.180 |
Why?
|
| Darunavir | 1 | 2021 | 30 | 0.180 |
Why?
|
| Epitopes | 2 | 2021 | 296 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2021 | 101 | 0.170 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 102 | 0.170 |
Why?
|
| Phylogeny | 6 | 2018 | 375 | 0.160 |
Why?
|
| Membrane Glycoproteins | 3 | 2016 | 669 | 0.160 |
Why?
|
| Genome, Viral | 2 | 2018 | 136 | 0.160 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 59 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 76 | 0.160 |
Why?
|
| Apoptosis | 2 | 2021 | 1071 | 0.160 |
Why?
|
| Models, Molecular | 7 | 2019 | 1146 | 0.160 |
Why?
|
| RNA, Viral | 3 | 2016 | 275 | 0.150 |
Why?
|
| Amino Acid Sequence | 8 | 2021 | 1595 | 0.150 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2018 | 181 | 0.150 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 464 | 0.150 |
Why?
|
| Cytidine | 1 | 2017 | 15 | 0.140 |
Why?
|
| CD4 Antigens | 1 | 2018 | 149 | 0.140 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2005 | 24 | 0.130 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2018 | 133 | 0.130 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 13 | 0.120 |
Why?
|
| Macrophages | 2 | 2018 | 1039 | 0.120 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2022 | 44 | 0.120 |
Why?
|
| Virus Latency | 1 | 2015 | 32 | 0.120 |
Why?
|
| Viral Load | 5 | 2016 | 231 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 570 | 0.110 |
Why?
|
| RNA | 1 | 2018 | 422 | 0.110 |
Why?
|
| Neutralization Tests | 4 | 2019 | 122 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 245 | 0.110 |
Why?
|
| Oropharynx | 1 | 2014 | 12 | 0.110 |
Why?
|
| Mothers | 3 | 2015 | 275 | 0.110 |
Why?
|
| Cytosine Deaminase | 1 | 2013 | 6 | 0.100 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 318 | 0.100 |
Why?
|
| Crystallography, X-Ray | 4 | 2017 | 432 | 0.100 |
Why?
|
| Infant | 6 | 2016 | 1623 | 0.100 |
Why?
|
| Genotype | 2 | 2018 | 666 | 0.100 |
Why?
|
| Transcriptome | 1 | 2015 | 385 | 0.090 |
Why?
|
| A549 Cells | 2 | 2022 | 39 | 0.090 |
Why?
|
| Substrate Specificity | 3 | 2018 | 337 | 0.090 |
Why?
|
| Adult | 8 | 2021 | 16673 | 0.090 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 58 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 31 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1997 | 0.090 |
Why?
|
| Gene Products, vif | 2 | 2007 | 9 | 0.090 |
Why?
|
| Protein Conformation | 3 | 2021 | 776 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 305 | 0.080 |
Why?
|
| Stavudine | 1 | 2010 | 3 | 0.080 |
Why?
|
| Nevirapine | 1 | 2010 | 8 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 413 | 0.080 |
Why?
|
| Human Growth Hormone | 1 | 2010 | 19 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 150 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 373 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1554 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 348 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 287 | 0.080 |
Why?
|
| Influenza Vaccines | 2 | 2021 | 98 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2003 | 641 | 0.070 |
Why?
|
| Child | 3 | 2010 | 4478 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 154 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2007 | 219 | 0.070 |
Why?
|
| Cryopreservation | 1 | 2008 | 29 | 0.070 |
Why?
|
| HIV Antigens | 1 | 2008 | 18 | 0.070 |
Why?
|
| HIV Core Protein p24 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Time Factors | 3 | 2014 | 3750 | 0.070 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2022 | 113 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 62 | 0.070 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 38 | 0.070 |
Why?
|
| Cell Line | 5 | 2018 | 2039 | 0.070 |
Why?
|
| Viral Envelope Proteins | 2 | 2005 | 102 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 45 | 0.070 |
Why?
|
| Acute Disease | 3 | 2016 | 671 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 263 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 66 | 0.070 |
Why?
|
| HIV Long-Term Survivors | 2 | 2005 | 8 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 91 | 0.060 |
Why?
|
| Female | 9 | 2021 | 32569 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 369 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2021 | 384 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 311 | 0.060 |
Why?
|
| APOBEC-3G Deaminase | 3 | 2012 | 21 | 0.060 |
Why?
|
| Male | 7 | 2021 | 29555 | 0.060 |
Why?
|
| Monkey Diseases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Callithrix | 1 | 2005 | 21 | 0.060 |
Why?
|
| Adolescent | 3 | 2015 | 6196 | 0.060 |
Why?
|
| Protein Structure, Secondary | 2 | 2017 | 260 | 0.060 |
Why?
|
| Alleles | 2 | 2007 | 449 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 3 | 2015 | 670 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2005 | 108 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1640 | 0.060 |
Why?
|
| Endopeptidases | 1 | 2004 | 67 | 0.060 |
Why?
|
| Protein Multimerization | 2 | 2018 | 174 | 0.060 |
Why?
|
| Lung | 3 | 2023 | 939 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2016 | 1962 | 0.060 |
Why?
|
| Binding Sites | 2 | 2018 | 902 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 95 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2016 | 300 | 0.050 |
Why?
|
| Amino Acid Motifs | 2 | 2018 | 153 | 0.050 |
Why?
|
| Genes, vpr | 1 | 2002 | 4 | 0.050 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Pneumonia | 1 | 2005 | 288 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2002 | 97 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2009 | 3263 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 193 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 487 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2005 | 623 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2016 | 242 | 0.050 |
Why?
|
| Gene Expression | 2 | 2018 | 838 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2023 | 219 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 135 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 2 | 2012 | 100 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2012 | 2156 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 129 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 867 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 95 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 121 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2021 | 610 | 0.040 |
Why?
|
| Animals | 6 | 2023 | 20624 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2012 | 84 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 1348 | 0.040 |
Why?
|
| Cross-Linking Reagents | 2 | 2012 | 120 | 0.040 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2019 | 22 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2012 | 146 | 0.040 |
Why?
|
| Reverse Genetics | 1 | 2019 | 10 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 36 | 0.040 |
Why?
|
| Proviruses | 1 | 2018 | 26 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2018 | 84 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 172 | 0.030 |
Why?
|
| Dogs | 1 | 2019 | 325 | 0.030 |
Why?
|
| Deamination | 1 | 2017 | 11 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 242 | 0.030 |
Why?
|
| Convalescence | 1 | 2016 | 18 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 900 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 78 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2018 | 144 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 455 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 364 | 0.030 |
Why?
|
| Protein Domains | 1 | 2017 | 148 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2021 | 708 | 0.030 |
Why?
|
| Genes, env | 1 | 2015 | 15 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 670 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 72 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 411 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 354 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 10823 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 264 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 109 | 0.030 |
Why?
|
| Dimerization | 1 | 2015 | 145 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Genomics | 1 | 2018 | 368 | 0.030 |
Why?
|
| Zinc | 1 | 2015 | 92 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 1335 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 691 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1115 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 749 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 258 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 636 | 0.030 |
Why?
|
| Catalysis | 1 | 2013 | 161 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1460 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2015 | 1508 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5596 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1252 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2010 | 2549 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 2012 | 18 | 0.020 |
Why?
|
| AIDS Vaccines | 1 | 2012 | 70 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 182 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 131 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 381 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2010 | 59 | 0.020 |
Why?
|
| Lamivudine | 1 | 2010 | 7 | 0.020 |
Why?
|
| Directly Observed Therapy | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cambodia | 1 | 2010 | 27 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 863 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 93 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 618 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 113 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 375 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2444 | 0.020 |
Why?
|
| Humidity | 1 | 2008 | 12 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2326 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 577 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 130 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2007 | 29 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 240 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2007 | 135 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 533 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 989 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 50 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 293 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1078 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 110 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 222 | 0.010 |
Why?
|
| Carboxypeptidases | 1 | 2003 | 8 | 0.010 |
Why?
|
| Giant Cells | 1 | 2003 | 15 | 0.010 |
Why?
|
| Vero Cells | 1 | 2003 | 80 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2005 | 216 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 188 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2003 | 73 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4655 | 0.010 |
Why?
|
| Myocardium | 1 | 2005 | 275 | 0.010 |
Why?
|
| Solubility | 1 | 2003 | 179 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2003 | 19 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 282 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 72 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 182 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 894 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2003 | 39 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 451 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1273 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 311 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2003 | 237 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1980 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 1142 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 775 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2180 | 0.010 |
Why?
|